Opthea Limited (ASX: OPT) has received commitments from sophisticated and institutional investors in Australia and the UK to raise $50 million through a private placement.
- The funds raised through the placement would support in the late-stage clinical development of OPT-302 as a treatment for wet Age-related Macular Degeneration (AMD).
- The funds would also be used in the production of adequate quantities of clinical grade OPT-302 for Phase 3 clinical development and the initiation of two simultaneous Phase 3 pivotal registrational trials in wet AMD patients.
At AEST: 1:05 PM, OPT shares quoted $3.09, up 13.3% from its previous close.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.